Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: perflutren

« Back to Dashboard
Perflutren is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and eight patent family members in thirty countries.

One supplier is listed for this compound.

Summary for Generic Name: perflutren

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: 0
Suppliers / Packaging: see list3
Formulation / Manufacturing:see details

Pharmacology for Ingredient: perflutren

Clinical Trials for: perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes6,033,645<disabled><disabled>
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes5,527,521<disabled>Y<disabled>
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes8,685,441<disabled><disabled>
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes8,658,205<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: perflutren

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,747,892Preparation of a lipid blend and a phospholipid suspension containing the lipid blend<disabled in preview>
5,736,121 Stabilized homogenous suspensions as computed tomography contrast agents<disabled in preview>
6,528,039 Low density microspheres and their use as contrast agents for computed tomography and in other applications<disabled in preview>
6,117,414 Method of computed tomography using fluorinated gas-filled lipid microspheres as contract agents<disabled in preview>
5,205,290 Low density microspheres and their use as contrast agents for computed tomography<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: perflutren

Country Document Number Publication Date
Canada2191079Nov 30, 1995
Russian Federation2199348Feb 27, 2003
European Patent Office0760684Mar 15, 2000
Australia2115599Aug 02, 1999
European Patent Office1419789May 26, 2004
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc